Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 9, Issue 6, Pages 1677
Publisher
MDPI AG
Online
2020-06-02
DOI
10.3390/jcm9061677
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pancreatic grade 3 neuroendocrine tumors behave similarly to neuroendocrine carcinomas following resection: a multi-center, international appraisal of the WHO 2010 and WHO 2017 staging schema for pancreatic neuroendocrine lesions
- (2020) Patrick J. Worth et al. HPB
- State of the Art: Evaluating the Role of Theranostics in G3 Neuroendocrine Neoplasms
- (2019) Naj L. Waseem et al. JOURNAL OF NUCLEAR MEDICINE
- Well-differentiated grade 3 neuroendocrine tumours and poorly differentiated grade 3 neuroendocrine carcinomas
- (2019) Sandip Basu et al. NUCLEAR MEDICINE COMMUNICATIONS
- Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177 Lu-Satoreotide Tetraxetan
- (2019) Diane Reidy-Lagunes et al. CLINICAL CANCER RESEARCH
- Chemotherapy in resected neuroendocrine carcinomas of the digestive tract: a national study from the French Group of Endocrine Tumours (GTE)
- (2019) Anna Pellat et al. NEUROENDOCRINOLOGY
- PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
- (2019) Halfdan Sorbye et al. ENDOCRINE-RELATED CANCER
- Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study
- (2018) Carlie S. Sigel et al. CANCER CYTOPATHOLOGY
- Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms
- (2018) Anna Pellat et al. NEUROENDOCRINOLOGY
- Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia
- (2018) Matthias M. Weber et al. Oncology Research and Treatment
- A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
- (2018) Pamela L. Kunz et al. JOURNAL OF CLINICAL ONCOLOGY
- Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms
- (2018) Robert T. Jensen et al. NEUROENDOCRINOLOGY
- Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
- (2017) T. Walter et al. EUROPEAN JOURNAL OF CANCER
- Whole-genome landscape of pancreatic neuroendocrine tumours
- (2017) Aldo Scarpa et al. NATURE
- Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms
- (2017) Louis de Mestier et al. NEUROENDOCRINOLOGY
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification
- (2017) Aurel Perren et al. NEUROENDOCRINOLOGY
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Pancreatic Neuroendocrine Carcinomas G3
- (2017) Francesco Panzuto et al. PANCREAS
- Prise en charge thérapeutique des tumeurs neuroendocrines peu différenciées pulmonaires et des carcinomes neuroendocrines digestifs
- (2016) Anna Pellat et al. BULLETIN DU CANCER
- Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications
- (2016) Nicola Fazio et al. CANCER TREATMENT REVIEWS
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey among French Pathologists (the PRONET Study)
- (2016) Jean-Yves Scoazec et al. NEUROENDOCRINOLOGY
- ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update
- (2016) Dermot O'Toole et al. NEUROENDOCRINOLOGY
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement
- (2016) Romain Coriat et al. ONCOLOGIST
- The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms
- (2015) Olca Basturk et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study
- (2015) Sven-Petter Haugvik et al. ANNALS OF SURGICAL ONCOLOGY
- Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice
- (2015) Anne-Sophie Dussol et al. CANCER
- Survival of Patients With Neuroendocrine Carcinoma of the Colon and Rectum
- (2015) Hammad Shafqat et al. DISEASES OF THE COLON & RECTUM
- Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma
- (2015) J. Hadoux et al. ENDOCRINE-RELATED CANCER
- Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
- (2015) M Heetfeld et al. ENDOCRINE-RELATED CANCER
- A Retrospective Review of 126 High-Grade Neuroendocrine Carcinomas of the Colon and Rectum
- (2014) James D. Smith et al. ANNALS OF SURGICAL ONCOLOGY
- Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) – A phase II non-randomised trial
- (2014) Michel Ducreux et al. EUROPEAN JOURNAL OF CANCER
- Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) – A phase II non-randomised trial
- (2014) Emmanuel Mitry et al. EUROPEAN JOURNAL OF CANCER
- Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies
- (2014) Michelle D Reid et al. MODERN PATHOLOGY
- Grading of Neuroendocrine Neoplasms: Mitoses and Ki-67 Are Both Essential
- (2014) Marie-Louise F. van Velthuysen et al. NEUROENDOCRINOLOGY
- Reliability of Proliferation Assessment by Ki-67 Expression in Neuroendocrine Neoplasms: Eyeballing or Image Analysis?
- (2014) Marie-Louise F. van Velthuysen et al. NEUROENDOCRINOLOGY
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
- (2014) Martyn E. Caplin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index
- (2013) B. Weynand et al. CYTOPATHOLOGY
- Are G3 ENETS neuroendocrine neoplasms heterogeneous?
- (2013) Fritz-Line Vélayoudom-Céphise et al. ENDOCRINE-RELATED CANCER
- Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: Experience of two decades of cancer registry
- (2013) Catharina M. Korse et al. EUROPEAN JOURNAL OF CANCER
- Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors
- (2012) Shinichi Yachida et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System
- (2012) Laura H. Tang et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
- (2012) H. Sorbye et al. ANNALS OF ONCOLOGY
- FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide–platinum combination in patients with neuroendocrine carcinomas grade 3
- (2012) O Hentic et al. ENDOCRINE-RELATED CANCER
- Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors
- (2012) Maxime Palazzo et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Feasibility and Efficacy of Combined Cisplatin and Irinotecan Chemotherapy for Poorly Differentiated Neuroendocrine Carcinomas
- (2012) K. Nakano et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors
- (2012) Massimo Falconi et al. NEUROENDOCRINOLOGY
- ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas
- (2012) Ulrich-Frank Pape et al. NEUROENDOCRINOLOGY
- ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
- (2012) Marianne Pavel et al. NEUROENDOCRINOLOGY
- Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract
- (2012) Magaly Zappa et al. Targeted Oncology
- Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy
- (2011) Staffan Welin et al. CANCER
- Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma
- (2011) Hedia Brixi-Benmansour et al. DIGESTIVE AND LIVER DISEASE
- Prognostic Validity of a Novel American Joint Committee on Cancer Staging Classification for Pancreatic Neuroendocrine Tumors
- (2011) Jonathan R. Strosberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
- (2011) Y. Jiao et al. SCIENCE
- First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
- (2010) Jonathan R. Strosberg et al. CANCER
- 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors
- (2010) T. Binderup et al. CLINICAL CANCER RESEARCH
- Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters
- (2010) Martin B Niederle et al. ENDOCRINE-RELATED CANCER
- Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET
- (2010) T. Binderup et al. JOURNAL OF NUCLEAR MEDICINE
- NANETS Treatment Guidelines
- (2010) Matthew H. Kulke et al. PANCREAS
- The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors
- (2010) J. Philip Boudreaux et al. PANCREAS
- The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine Carcinomas
- (2010) Jonathan R. Strosberg et al. PANCREAS
- Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas
- (2009) Philippe A. Cassier et al. CANCER
- Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon α for advanced carcinoid tumors: FNCLCC–FFCD 9710
- (2009) Laetitia Dahan et al. ENDOCRINE-RELATED CANCER
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started